7 completed, 3 recruiting, 2 active not recruiting, 1 suspended. 14 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 7, Recruiting 3, Active not recruiting 2, Suspended 1, Unknown 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Non-cystic Fibrosis Bronchiectasis: new trials by email Literature Review of Non-cystic Fibrosis Bronchiectasis trials Research Report on Non-cystic Fibrosis Bronchiectasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis Galvokimig, Placebo - Non-cystic Fibrosis Bronchiectasis | Phase 2 | Recruiting | UCB Biopharma SRL | 300 | 2026-08-05 | 2026-11-06 |
| A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis SAR445399, Placebo - Non-cystic Fibrosis Bronchiectasis | Phase 2 | Suspended | Sanofi | 70 | 2026-06-08 | 2026-07-29 |
| Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB) CSL787, Placebo, Nebulizer - Non-cystic Fibrosis Bronchiectasis | Phase 2 | Recruiting | CSL Behring | 180 | 2025-09-03 | 2026-10-19 |
| A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis XH-S004 20 mg, XH-S004 40 mg, Placebo - Non-Cystic Fibrosis Bronchiectasis | Phase 2 | Active not recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 234 | 2025-05-30 | 2026-09-25 |
| Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa) RESP302, RESP303 - Non-Cystic Fibrosis Bronchiectasis | Phase 1 / Phase 2 | Active not recruiting | Thirty Respiratory Limited | 60 | 2024-10-16 | 2026-03-10 |
| A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis Nebulized Ensifentrine Suspension; 3 mg, Nebulized Placebo Solution - Non-cystic Fibrosis Bronchiectasis | Phase 2 | Recruiting | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 284 | 2024-09-11 | 2026-10-27 |
| Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection AP-PA02, Placebo - Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa | Phase 2 | Completed | Armata Pharmaceuticals, Inc. | 48 | 2023-01-10 | 2026-01-05 |
| Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough ARINA-1, Placebo - Non-cystic Fibrosis Bronchiectasis | Phase 2 | Completed | Renovion, Inc. | 40 | 2022-10-03 | 2025-07-23 |
| Roflumilast in Non-CF Bronchiectasis Study (2019) Roflumilast Oral Tablet - Non-cystic Fibrosis Bronchiectasis | Phase 2 | Completed | The University of Hong Kong | 42 | 2020-11-12 | 2024-12-09 |
| Inhalations of Ultra-low Doses of Melphalan for the Treatment of Non-cystic Fibrosis Bronchiectasis Melphalan - Non-cystic Fibrosis Bronchiectasis | Phase 2 | Unknown | Federal State Budgetary Institution, Pulmonology Scientific Research Institute | 7 | 2018-06-20 | 2020-02-20 |
| Roflumilast in Non-CF Bronchiectasis Study Oral roflumilast - Non-cystic Fibrosis Bronchiectasis | Phase 2 | Completed | The University of Hong Kong | 20 | 2018-05-10 | 2019-10-01 |
| Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis Brensocatib 10 mg, Brensocatib 25 mg, Placebo - Non-Cystic Fibrosis Bronchiectasis | Phase 2 | Completed | Insmed Incorporated | 256 | 2017-10-31 | 2023-03-27 |
| Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection TIP, TIP and placebo, Placebo - Non-cystic Fibrosis Bronchiectasis | Phase 2 | Completed | Novartis Pharmaceuticals | 107 | 2017-02-08 | 2020-08-25 |
| Safety and Efficacy Study of Ciprofloxacin for Inhalation in Patients With Non-Cystic Fibrosis Bronchiectasis "ORBIT-1" Ciprofloxacin for Inhalation, Placebo - Non-Cystic Fibrosis Bronchiectasis | Phase 2 | Completed | Aradigm Corporation | 95 | 2010-02-01 | 2017-01-25 |
Bronchiectasis (6) · Pseudomonas Infections (2) · Respiratory Aspiration (2) · Fibrosis (1) · Inflammation (1)
Respiratory Tract Diseases (7) · Bronchial Diseases (6) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Bacterial Infections (2) · Bacterial Infections and Mycoses (2) · Gram-Negative Bacterial Infections (2) · Infections (2) · Respiration Disorders (2)
Roflumilast (2) · Ciprofloxacin (1) · Inhalation (1) · Lysine Acetyltransferase 5 (1) · Melphalan (1) · Nebulizers and Vaporizers (1) · brensocatib (1)
The University of Hong Kong (2) · Aradigm Corporation (1) · Armata Pharmaceuticals, Inc. (1) · CSL Behring (1) · Federal State Budgetary Institution, Pulmonology Scientific Research Institute (1) · Insmed Incorporated (1) · Novartis Pharmaceuticals (1) · Renovion, Inc. (1) · Sanofi (1) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (1) · Thirty Respiratory Limited (1) · UCB Biopharma SRL (1) · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (1)
United States (7) · United Kingdom (4) · Germany (3) · Italy (3) · Spain (3) · Australia (2) · Belgium (2) · Hong Kong (2) · Bulgaria (1) · Canada (1) · China (1) · Denmark (1) · France (1) · Japan (1) · Netherlands (1)
Carlos Fernandez, MD (1) · Charles L Daley, MD (1) · James CM Ho, MD (1) · Kirill Zykov, Prof (1) · Paul Bruinenberg, MBChB, MBA (1)
PMID 31433997, PMID 32855225, PMID 32897034, PMID 37198686, PMID 37538173, PMID 39938076
2015 (1), 2017 (1), 2025 (1)